A low dibucaine number can suggest an inherited enzyme variant that prolongs paralysis after succinylcholine or mivacurium. Tell your anesthesiologist before treatment; the result measures enzyme behavior, not how much enzyme activity you have.
- Dibucaine number test measures the percentage of plasma cholinesterase activity inhibited by dibucaine; it does not measure enzyme quantity.
- Usual enzyme phenotype commonly produces a dibucaine number around 80, although the laboratory's method-specific interval takes priority.
- លទ្ធផលកម្រិតមធ្យម around 40–70 can suggest one usual and one atypical BCHE allele, but the number alone cannot establish a genotype.
- Very low results below approximately 30 strongly suggest an atypical enzyme phenotype when there is enough activity for reliable testing.
- Enzyme activity is usually reported in U/L and can fall with pregnancy, liver dysfunction, illness, or medication exposure even when the dibucaine number remains usual.
- Anesthesia risk concerns prolonged paralysis and inadequate breathing after succinylcholine or mivacurium; severe inherited deficiency can extend recovery for several hours.
- Before a procedure share both test results, any BCHE genetic report, and details of previous prolonged ventilation with your anesthesiologist.
- ការធ្វើតេស្តសម្រាប់គ្រួសារ is reasonable for first-degree relatives when inherited deficiency is confirmed or strongly suspected, especially before anesthesia.
- Normal inhibition results do not exclude every BCHE variant or other causes of delayed recovery; paired activity testing and clinical history remain necessary.
What does the dibucaine number test actually measure?
នេះ។ dibucaine number test measures how strongly dibucaine inhibits your plasma cholinesterase enzyme. A low result suggests an atypical enzyme that may clear succinylcholine or mivacurium slowly, so your anesthesiologist needs the result before either drug is considered.
A dibucaine number of 80 means that dibucaine inhibited approximately 80% of measured enzyme activity under that laboratory's assay conditions. It does not mean that your enzyme works at 80% of normal, and it is not a percentage estimate of anesthesia safety.
Dibucaine is added to the laboratory assay, not administered to you as part of this test. The laboratory compares enzyme activity with and without the inhibitor; this distinction often reassures someone who recognizes dibucaine as a local anesthetic and worries about receiving another potentially risky medication.
កាន់តេស្ទី គឺជា ឧបករណ៍វិភាគឈាម AI that can help explain why a dibucaine number near 80 and a low activity result describe different findings. Our អង្គការ និងគោលបំណងគ្លីនិករបស់យើង are separate from the anesthesiologist's responsibility to select drugs and monitor recovery.
My editorial approach as Thomas Klein, MD, is to start with 2 separate questions: does the enzyme behave unusually, and is there enough functional activity? A report answering only one question can be useful, but it should not be treated as a complete pseudocholinesterase deficiency assessment.
How is the dibucaine number different from cholinesterase activity?
Cholinesterase activity measures the enzyme's overall reaction rate, usually in U/L; the dibucaine number measures its susceptibility to inhibition. Activity reflects both enzyme amount and function, whereas inhibition testing helps identify certain qualitative enzyme variants.
The enzyme involved is butyrylcholinesterase, also called plasma cholinesterase or pseudocholinesterase. It is different from acetylcholinesterase at the neuromuscular junction; ordering a red-cell acetylcholinesterase measurement does not substitute for the paired plasma tests used to investigate succinylcholine sensitivity.
The underlying calculation is 100 × [1 − activity with dibucaine ÷ activity without dibucaine]. If the uninhibited reaction rate is 100 arbitrary assay units and the inhibited rate is 20, the dibucaine number is 80; both reactions could be much slower overall while retaining that same ratio.
Kalow and Genest introduced dibucaine inhibition testing in 1957 to distinguish atypical forms of human serum cholinesterase. Their paper explains the central insight: a drug inhibitor can reveal an enzyme's qualitative behavior, rather than merely identifying a low concentration of enzyme (Kalow & Genest, 1957).
Two reports should therefore be read together: plasma cholinesterase activity and dibucaine inhibition. Our explanation of លទ្ធផលគុណភាព ទល់នឹង លទ្ធផលបរិមាណ helps clarify why a phenotype assessment and an activity measurement are complementary, not competing answers.
How should low dibucaine numbers be interpreted?
A usual dibucaine number is commonly near 80, an intermediate result around 40–70 can suggest an atypical carrier phenotype, and a result below approximately 30 strongly suggests an atypical phenotype. These are teaching ranges, not universal diagnostic cutoffs.
Laboratories differ in assay substrate, temperature, inhibitor concentration, and reporting conventions. A result of 70 may fall inside one laboratory's interval and near the boundary in another; the printed reference interval is more useful than a cutoff borrowed from an unrelated laboratory website.
A number of 55 with measurable activity is compatible with an intermediate inhibition phenotype, but it does not prove a specific BCHE allele combination. A number of 22 deserves particularly clear preoperative documentation because it is compatible with the classic atypical phenotype associated with substantially prolonged drug effects.
Borderline values should trigger clarification rather than automatic labeling. If the laboratory reports 35, ask whether the result is reproducible, whether activity was sufficient for interpretation, and whether further phenotyping or genetic testing would distinguish an unusual variant from analytical uncertainty.
A low result is an exposure-dependent medication risk, not evidence that you are currently unable to breathe normally. This is conceptually similar to DPYD medication-safety testing: the result matters because a future drug may expose a vulnerability that is otherwise clinically silent.
What does a low result suggest about inherited BCHE deficiency?
A persistently low dibucaine number suggests an inherited BCHE enzyme variant, especially the classic atypical variant. Clinically significant inherited pseudocholinesterase deficiency often involves 2 affected alleles, but carriers can also experience prolonged effects after susceptible medications.
The BCHE gene encodes butyrylcholinesterase, an enzyme produced mainly in the liver and released into circulation. A person with 1 atypical allele may have an intermediate inhibition pattern; a person with 2 atypical alleles may have a much lower number, although other allele combinations complicate this familiar pattern.
A genetic result and a functional result are not interchangeable. Lockridge's 2015 review describes multiple butyrylcholinesterase variants and their clinical relevance, including variants affecting enzyme quantity, catalytic properties, or inhibitor response (Lockridge, 2015); the dibucaine assay recognizes only part of that biological variation.
ចូរពិចារណាគំរូមួយ អាយុ 34 ឆ្នាំ whose parent needed unexpected ventilation after anesthesia and whose dibucaine number is 54. I would regard that combination as a reason for an anesthesia safety plan and further assessment, not as proof that the patient will have the same recovery time as their parent.
Kantesti explains this result as a possible drug-metabolism vulnerability, not an illness requiring daily treatment. Our discussion of TPMT enzyme testing illustrates the broader distinction between an inherited enzyme finding and the medication exposure that makes it clinically relevant.
Can cholinesterase activity be low without inherited deficiency?
Yes. Pregnancy, significant liver dysfunction, malnutrition, severe illness, certain medications, and organophosphate exposure can reduce plasma cholinesterase activity without producing the classic low dibucaine number associated with an atypical inherited enzyme.
Pregnancy commonly reduces plasma cholinesterase activity by roughly 20–30%, although the magnitude varies. This does not mean every pregnant patient has dangerous drug sensitivity; it means pregnancy can add to an inherited or acquired reduction, particularly when the baseline activity was already low.
Liver disease can reduce enzyme synthesis even though AST and ALT measure a different process: cellular injury rather than synthetic capacity. Our មគ្គុទ្ទេសក៍ពាក្យកាត់សម្រាប់ការធ្វើតេស្តថ្លើមរបស់យើង explains why a normal transaminase result cannot establish normal cholinesterase activity or rule out an inherited enzyme variant.
Albumin and INR may help assess hepatic synthetic function, but neither substitutes for a pseudocholinesterase deficiency test. The មគ្គុទ្ទេសក៍បកស្រាយប្រូតេអ៊ីនក្នុងឈាម provides background for interpreting these accompanying results when liver dysfunction or nutritional depletion is suspected.
A hypothetical activity of 4,200 U/L would be low if that particular laboratory's interval were 5,000–12,000 U/L, but another method may use a very different interval. If the dibucaine number is 81, I would investigate acquired causes and baseline activity rather than calling that paired pattern classic atypical inherited deficiency.
Why do succinylcholine and mivacurium create anesthesia risk?
Succinylcholine and mivacurium depend on plasma butyrylcholinesterase for rapid breakdown. Reduced activity or an atypical enzyme can prolong their neuromuscular-blocking effects, leaving a patient unable to move or breathe adequately until the drug effect resolves.
Succinylcholine usually has a clinical duration of approximately 5–10 minutes after a typical single intravenous dose, while mivacurium is also relatively short acting. These are not guaranteed recovery times: dose, repeat administration, temperature, other medicines, and the depth of blockade all influence the actual clinical course.
These drugs produce paralysis, not unconsciousness or pain relief. Adequate anesthesia or sedation must therefore continue if paralysis persists; a patient who cannot move may still need protection from awareness even when the original procedure has finished.
A low dibucaine number does not predict every succinylcholine complication. Hyperkalemia and malignant hyperthermia involve separate risk mechanisms, and disorders affecting neuromuscular transmission require their own assessment; our myasthenia testing explanation discusses one such distinct clinical problem.
Anesthesiologists can often choose drugs that do not rely on butyrylcholinesterase, such as rocuronium or cisatracurium, depending on the procedure and patient. The appropriate agent, monitoring, and any reversal strategy depend on airway needs, organ function, available equipment, and the clinician's plan—not on the dibucaine number alone.
What happens if paralysis lasts longer than expected?
Unexpected prolonged paralysis requires continued airway support, ventilation, appropriate sedation, and neuromuscular monitoring while clinicians investigate the cause. In severe inherited pseudocholinesterase deficiency, succinylcholine-related recovery can take several hours rather than the usual few minutes.
Recovery of approximately 2–8 hours is described with the classic severe atypical phenotype, but the range is not a prediction for an individual patient. An intermediate number, a different dose, or a mixed inherited-and-acquired reduction may produce a shorter or longer course.
Clinicians should exclude other explanations for delayed recovery, including residual nondepolarizing blockade, sedative effects, low temperature, and metabolic disturbances. Quantitative train-of-four monitoring helps assess neuromuscular recovery; oxygen saturation alone does not establish normal ventilation or recovered muscle strength.
Cornelius and Jacobs' 2020 Anesthesia Progress case study discusses recognition and management of pseudocholinesterase deficiency during delayed recovery (Cornelius & Jacobs, 2020). Supportive care is usually preferred to transfusing plasma solely to accelerate recovery because transfusion introduces risks and the drug effect generally resolves with monitored support.
Kantesti cannot determine whether a recovering patient is safe for extubation from a laboratory report. Our arterial gas result guide explains relevant respiratory measurements, but airway decisions require bedside assessment; new breathing difficulty after discharge warrants emergency medical attention.
When should the sample be collected, and is fasting needed?
Dibucaine inhibition and plasma cholinesterase activity are ideally tested before a planned anesthetic when risk is suspected. Fasting is generally unnecessary for these assays alone, but the collecting laboratory's instructions and the timing of recent anesthesia take priority.
After unexpected prolonged paralysis, clinicians can arrange investigation once the immediate problem has been managed. Some laboratories request waiting at least 48 hours after succinylcholine exposure for functional testing; requirements differ, so the anesthesia team should confirm the receiving laboratory's protocol rather than assume that timing is universal.
A recent plasma-containing transfusion can introduce donor enzyme and alter the functional phenotype being measured. Record the product and date, along with pregnancy status, acute illness, and medication exposure; a genetically atypical enzyme can be harder to recognize if the circulating sample temporarily contains a mixture.
Sample type matters: the laboratory may require serum or a specified plasma specimen, and not every anticoagulant is acceptable for every method. Our first laboratory draw preparation explains why following the actual requisition is safer than choosing a tube based on an internet description.
A visibly compromised specimen can also require laboratory review or recollection. The sample hemolysis explanation describes why interference is assay-specific; ask whether interference affected the cholinesterase measurement rather than assuming every flagged sample either invalidates or preserves the dibucaine result.
What can a normal or low dibucaine number miss?
The dibucaine number does not identify every BCHE variant, and a normal result does not exclude low enzyme activity or all anesthesia-related drug sensitivity. Very low underlying activity may make the inhibition ratio unreliable or impossible to report.
Rare fluoride-resistant, silent, or other BCHE variants may not fit the classic usual/intermediate/atypical dibucaine pattern. A silent variant can leave too little enzyme activity to phenotype meaningfully; dividing 2 tiny assay signals does not necessarily produce a clinically trustworthy percentage.
An apparently usual number of 82 can coexist with significantly reduced activity, so it is not a blanket clearance for succinylcholine. Conversely, a low number does not establish the exact duration of paralysis, because drug dose, activity, mixed variants, and acquired modifiers influence recovery together.
កាន់តេស្ទី គឺជា សេវាកម្មបកស្រាយការធ្វើតេស្តរបស់ AI lab that should treat missing activity data as missing—not infer it from an inhibition number. Our ក្របខណ្ឌសុពលភាពផ្នែកព្យាបាល describes why source results, method-specific ranges, and uncertainty need to remain visible in an explanation.
Unexpected phenotype results can require repeat measurement or a different testing approach. Our discussion of G6PD functional testing limits provides a useful parallel, although the mechanisms differ: enzyme assays answer questions about the specimen tested and do not automatically reveal every inherited variant.
When is BCHE genetic testing useful?
BCHE genetic testing is useful when functional results suggest inherited deficiency, family history is compelling, or an unexplained anesthesia event remains unresolved. It can clarify inheritance, but the usefulness of a negative result depends on which variants the test actually assesses.
A targeted test may examine only selected common variants, while sequencing evaluates a broader portion of the gene. These are 2 different scopes of testing: a negative targeted panel does not prove that every possible BCHE-related cause has been excluded.
Genetic testing can be particularly helpful after transfusion or during an acquired reduction in enzyme activity because DNA testing does not measure the circulating enzyme mixture. The laboratory still needs to know the clinical question, and unusual circumstances such as stem-cell transplantation can affect specimen selection for genetic analysis.
A variant of uncertain significance is not equivalent to a confirmed explanation for prolonged paralysis. Its interpretation may require functional testing, family segregation, published evidence, or later reclassification; anesthesia precautions can still be reasonable when the clinical history is convincing even before the variant is fully understood.
The strongest assessment combines the anesthetic record, quantitative activity, inhibition phenotype, and appropriately selected DNA testing. Our alpha-1 antitrypsin family-risk guide explains a similar diagnostic principle: concentration, protein behavior, and genotype can contribute different pieces of an inherited-enzyme or protein puzzle.
Which relatives should consider testing?
First-degree relatives—parents, siblings, and children—should discuss testing when inherited pseudocholinesterase deficiency is confirmed or strongly suspected. Testing is particularly useful before anesthesia, but the appropriate assay depends on whether the family's specific BCHE variants are known.
For a simple recessive condition where both parents carry 1 relevant affected allele, each pregnancy has a 25% chance of inheriting 2 affected alleles, a 50% chance of inheriting 1, and a 25% chance of inheriting neither. BCHE families can have mixed variants, so these percentages apply only when that parental genetic model is established.
The absence of a previous anesthesia problem does not exclude inherited risk. A relative may never have received succinylcholine or mivacurium, or may have received a different muscle relaxant; an uncomplicated procedure therefore provides much less reassurance than many families understandably assume.
Children do not need to wait until symptoms appear, because this condition is often silent outside drug exposure. Our risk-based family test planning supports targeted testing linked to an actionable family finding rather than broad laboratory panels for everyone.
Kantesti's Family Health Risk feature cannot infer a child's BCHE genotype from a parent's uploaded report. Our multigenerational consent guidance explains why adult relatives should control their own records; a family warning should prompt individual assessment, not an unverified diagnosis copied across accounts.
What should you tell your anesthesiologist before surgery?
Tell your anesthesiologist about a low dibucaine number, low cholinesterase activity, confirmed BCHE variant, or previous prolonged ventilation before the day of surgery whenever possible. Share the original report rather than relying on a remembered number or a generic allergy entry.
Bring 3 kinds of information if available: the paired laboratory results with reference intervals, the genetic report, and the anesthetic record from any delayed recovery. The actual drug, dose, timing, and duration of assisted ventilation help distinguish suspected pseudocholinesterase deficiency from other causes of a slow awakening.
A medical-alert bracelet or an electronic medication warning can make the finding easier to recognize during emergencies. Suggested wording is 'Pseudocholinesterase deficiency or suspected BCHE-related sensitivity—review before succinylcholine or mivacurium'; this identifies the risk without incorrectly describing it as an immune-mediated allergy.
A normal preoperative CBC, metabolic panel, PT, or aPTT does not screen for this enzyme problem. Our explanation of normal coagulation test limits addresses why normal routine testing should not override a specific history of a medication-related anesthesia event.
នេះ។ coagulation marker background guide covers a different preoperative safety question, not an alternative pseudocholinesterase deficiency test. Also mention the finding before electroconvulsive therapy or another procedure using muscle relaxation; it does not mean all anesthesia or all local anesthetics must be avoided.
How can AI help interpret paired results without overcalling risk?
AI can help organize dibucaine inhibition, cholinesterase activity, laboratory ranges, and clinical history, but it cannot provide anesthesia clearance. The safest interpretation preserves the distinction between a suspected enzyme phenotype and a confirmed genetic diagnosis.
កាន់តេស្ទី គឺជា វេទិកាបកស្រាយការធ្វើតេស្តឈាម AI that can put a number of 24 alongside the activity result and explain why the combination needs clinician review. The បច្ចេកវិទ្យានិងការណែនាំការបកស្រាយ describes the broader workflow; a specialized assay still needs its original laboratory commentary.
A scanned report can lose a decimal point, a unit, or a qualifier such as 'insufficient activity for interpretation'. របស់យើង។ បញ្ជីត្រួតពិនិត្យកំហុសការទាញយក PDF is especially relevant when a percentage-style inhibition result and a U/L activity measurement sit on adjacent lines.
A practical review should retain 4 source details: the exact assay name, result, reference interval, and collection date. Medication exposure, pregnancy, transfusion, and previous anesthesia events then supply context; a confident-sounding explanation is not useful if it quietly drops one of those limitations.
As Thomas Klein, MD, I would not turn a single uploaded number into a prediction of recovery time. The useful output is a focused question for the treating team—'Does this paired pattern justify avoiding BCHE-dependent relaxants, repeating functional testing, or arranging genetics?'—rather than an automated promise that surgery is safe.
Research publications and the limits of supporting evidence
The most directly relevant evidence comes from dibucaine assay research, BCHE variant reviews, and anesthesia reports. As of October 9, 2026, the practical approach remains to combine functional results with clinical history rather than use a single universal number to authorize a medication.
នេះ។ 1957 Kalow–Genest paper established the inhibitor-based approach, and Lockridge's 2015 review explains why BCHE variation extends beyond the familiar atypical phenotype. Cornelius and Jacobs' 2020 case study adds a clinical management perspective; these sources answer related but different questions, so none supplies a personalized paralysis-duration calculator.
នេះ។ 2 Zenodo resources listed below are background guides on coagulation and serum proteins. They are not studies validating the dibucaine number test, and a DOI alone does not establish peer review, clinical guideline status, or evidence for a specific anesthesia decision.
The formal citations use n.d. because verified publication dates and authorship metadata were not supplied for those 2 resources. ResearchGate and Academia.edu links are title-search links for discovery, not verified copies or endorsements; the DOI links identify the supplied Zenodo records.
របស់ Kantesti ការទទួលខុសត្រូវផ្នែកវេជ្ជសាស្ត្រ are relevant to medical content governance, but an informational article cannot replace review by the anesthesiologist caring for you. Before a planned procedure, make the paired report available and ask for the medication warning to be documented; that is more useful than repeatedly retesting an established inherited phenotype without a clinical reason.
សំណួរដែលសួរញឹកញាប់
លេខឌីបូកេនទាបមានន័យយ៉ាងណា?
លទ្ធផលលេខ dibucaine ទាបមានន័យថា dibucaine បានរារាំងសកម្មភាព cholinesterase ប្លាស្មាដែលបានវាស់តិចជាងការរំពឹងទុក ដែលបង្ហាញពីលក្ខណៈអង់ស៊ីមមិនធម្មតា។ លទ្ធផលប្រហែល 40–70 អាចបង្ហាញពីលក្ខណៈមធ្យម ខណៈដែលតម្លៃក្រោម 30 ប្រហែលជាបង្ហាញយ៉ាងខ្លាំងពីលក្ខណៈមិនធម្មតា នៅពេលដែលការធ្វើតេស្តមានភាពជឿជាក់។ លទ្ធផលតែឯងមិនបានកំណត់ហ្សែន BCHE ត្រឹមត្រូវ ឬព្យាករណ៍ពីរយៈពេលនៃការជាសះស្បើយទេ។ ចែករំលែកវាជាមួយគ្រូពេទ្យស្ពឹករបស់អ្នក ព្រោះ succinylcholine ឬ mivacurium អាចបណ្តាលឱ្យខ្វិនរយៈពេលយូរ។.
លេខ dibucaine ចំនួន 80 គឺជារឿងធម្មតាទេ?
លេខ dibucaine ប្រហែល 80 ជាធម្មតាត្រូវគ្នានឹងប្រភេទអង់ស៊ីមដែលងាយនឹង dibucaine ។ វាមានន័យថាការទប់ស្កាត់ប្រហែល 80% ក្រោមលក្ខខណ្ឌនៃការវិភាគ មិនមែន 80% នៃសកម្មភាពអង់ស៊ីមធម្មតាទេ។ ចន្លោះយោងរបស់មន្ទីរពិសោធន៍មានអាទិភាព ព្រោះវិធីសាស្ត្រមានភាពខុសគ្នា។ លេខធម្មតាមិនរាប់បញ្ចូលសកម្មភាព cholinesterase ទាប គ្រប់ប្រភេទ BCHE ឬហានិភ័យផ្សេងទៀតនៃការប្រើថ្នាំសន្លប់។.
តើសកម្មភាពកូលីណេស្តេរ៉ាស់អាចទាបដោយមានលេខឌីប៊ូកាអ៊ីនធម្មតាបានទេ?
បាទ/ចាស Plasma cholinesterase activity អាចទាបបាន ខណៈដែលលេខ dibucaine នៅតែជិត 80។ ការមានផ្ទៃពោះ, មុខងារថ្លើមមិនប្រក្រតី, ជំងឺធ្ងន់ធ្ងរ, ជំងឺខ្វះអាហារូបត្ថម្ភ, ថ្នាំមួយចំនួន, និងការប៉ះពាល់នឹង organophosphate អាចកាត់បន្ថយសកម្មភាពដោយមិនបង្កឱ្យមានលំនាំការរារាំង atypical បែបបុរាណនោះទេ។ សកម្មភាពជាធម្មតាត្រូវបានរាយការណ៍ជា U/L ខណៈដែលលេខ dibucaine រៀបរាប់ពីភាគរយនៃការរារាំង។ ការវាស់វែងទាំងពីរ និងប្រវត្តិវេជ្ជសាស្ត្រគឺចាំបាច់ដើម្បីវាយតម្លៃហានិភ័យនៃការស្ពឹក។.
How long can succinylcholine last with pseudocholinesterase deficiency?
Succinylcholine usually has a clinical duration of roughly 5–10 minutes after a typical single intravenous dose, but severe inherited pseudocholinesterase deficiency can prolong paralysis for several hours. Recovery of approximately 2–8 hours is described with the classic severe atypical phenotype, although individual courses vary. Dose, enzyme activity, genetic variants, temperature, and other medications affect recovery. Treatment generally involves monitored ventilation and continued appropriate sedation until neuromuscular function returns.
Should family members get a pseudocholinesterase deficiency test?
First-degree relatives should discuss testing when inherited pseudocholinesterase deficiency is confirmed or strongly suspected, especially before anesthesia. If both parents carry 1 relevant affected allele in a simple recessive model, each pregnancy has a 25% chance of inheriting 2 affected alleles. Testing may include plasma cholinesterase activity, dibucaine inhibition, or targeted testing for a known familial BCHE variant. An uneventful previous anesthetic does not exclude risk if the relative never received a susceptible drug.
Do I need to fast before a dibucaine number test?
Fasting is generally unnecessary for the dibucaine number test and plasma cholinesterase activity alone, but follow the collecting laboratory's instructions. Recent anesthesia, transfusion, pregnancy, and illness may affect interpretation more than a meal. Some laboratories request at least 48 hours after succinylcholine exposure before functional testing, but this is not a universal rule. Ask the ordering clinician or laboratory about specimen type and timing rather than stopping prescribed medicines yourself.
Can I still have surgery with a low dibucaine number?
A low dibucaine number does not automatically prevent surgery, because anesthesiologists can plan around the medication risk. Share 3 types of records if available: paired laboratory results, BCHE genetic findings, and documentation of any previous prolonged ventilation. Alternatives such as rocuronium or cisatracurium do not depend on butyrylcholinesterase metabolism, although the choice must suit your overall clinical situation. Tell the anesthesia team before the procedure rather than relying solely on an electronic allergy label.
ទទួលការវិភាគឈាមដោយ AI ដែលមានថាមពលថ្ងៃនេះ
ចូលរួមជាមួយអ្នកប្រើប្រាស់ជាង 2 លាននាក់នៅទូទាំងពិភពលោក ដែលទុកចិត្ត Kantesti សម្រាប់ការវិភាគលទ្ធផលតេស្តមន្ទីរពិសោធន៍ភ្លាមៗ និងត្រឹមត្រូវ។ ផ្ទុកឡើងលទ្ធផលពិនិត្យឈាមរបស់អ្នក ហើយទទួលការបកស្រាយយ៉ាងទូលំទូលាយនៃសញ្ញាសម្គាល់ (biomarkers) 15,000+ ក្នុងរយៈពេលប៉ុន្មានវិនាទី។.
📚 ឯកសារស្រាវជ្រាវដែលបានយោង
Klein, T., Mitchell, S., & Weber, H. (2026). ជួរធម្មតា aPTT៖ D-Dimer, ប្រូតេអ៊ីន C ការណែនាំអំពីការកកឈាម.។ ការស្រាវជ្រាវវេជ្ជសាស្ត្រដោយ AI របស់ Kantesti។.
Klein, T., Mitchell, S., & Weber, H. (2026). ការណែនាំអំពីប្រូតេអ៊ីនសេរ៉ូម៖ ការធ្វើតេស្តឈាមសម្រាប់គ្លូប៊ុយលីន អាល់ប៊ុយមីន និងសមាមាត្រ A/G.។ ការស្រាវជ្រាវវេជ្ជសាស្ត្រដោយ AI របស់ Kantesti។.
📖 ឯកសារយោងវេជ្ជសាស្ត្រខាងក្រៅ
Kalow W, Genest K. (1957). A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. Canadian Journal of Biochemistry and Physiology.
Lockridge O. (2015). Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses.។ ឱសថសាស្ត្រ និងការព្យាបាល (Pharmacology & Therapeutics)។.
Cornelius BW, Jacobs TM. (2020). Pseudocholinesterase Deficiency Considerations: A Case Study. Anesthesia Progress.
⚕️ ការបដិសេធផ្នែកវេជ្ជសាស្ត្រ
អត្ថបទនេះមានគោលបំណងសម្រាប់ការអប់រំប៉ុណ្ណោះ ហើយមិនមែនជាការផ្តល់ដំបូន្មានផ្នែកវេជ្ជសាស្ត្រទេ។ សូមពិគ្រោះជាមួយអ្នកផ្តល់សេវាសុខភាពដែលមានសមត្ថភាពជានិច្ច សម្រាប់ការសម្រេចចិត្តអំពីការធ្វើរោគវិនិច្ឆ័យ និងការព្យាបាល។.
សញ្ញាទុកចិត្ត E-E-A-T
បទពិសោធន៍
ការពិនិត្យព្យាបាលដោយវេជ្ជបណ្ឌិតលើដំណើរការការបកស្រាយលទ្ធផលមន្ទីរពិសោធន៍។.
ជំនាញ
ផ្តោតលើវិទ្យាសាស្ត្រមន្ទីរពិសោធន៍ថា សញ្ញាសម្គាល់ (biomarkers) មានឥរិយាបថយ៉ាងដូចម្តេចក្នុងបរិបទព្យាបាល។.
ភាពមានសិទ្ធិអំណាច
សរសេរដោយវេជ្ជបណ្ឌិត Thomas Klein ជាមួយការពិនិត្យឡើងវិញដោយវេជ្ជបណ្ឌិត Sarah Mitchell និងសាស្ត្រាចារ្យវេជ្ជបណ្ឌិត Hans Weber។.
ភាពគួរឱ្យទុកចិត្ត
ការបកស្រាយដោយផ្អែកលើភស្តុតាង ជាមួយផ្លូវបន្តតាមដានច្បាស់លាស់ ដើម្បីកាត់បន្ថយការភ័យខ្លាច។.